Antitumor drug with double active components and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of anti-tumor drugs and active ingredients, applied in the field of anti-tumor drugs, can solve the problems of unsatisfactory tumor treatment effects, and achieve clear and significant anti-tumor effects, significant anti-tumor activity, and enhanced inhibitory effects
Active Publication Date: 2011-09-28
MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI +1
View PDF3 Cites 5 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0023] Experiments have proved that the effect of using the above drugs alone is not very satisfactory for tumor treatment. Therefore, ho...
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0061] Recipe: Dipyridamole is 1mg, 5mg, 50mg, 100mg, 200mg, 400mg, 800mg or 1600mg respectively, Ubenimex is 1mg, 10mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1600mg or 3200mg respectively. Pyridamole and Ubenimex are stirred and mixed.
Embodiment 2
[0063] Recipe: dipyridamole is 1mg, 5mg, 50mg, 100mg, 200mg, 400mg, 800mg or 1600mg respectively, and dexamethasone is 0.1mg, 1mg, 10mg, 20mg, 40mg, 80mg or 160mg respectively. Stir dipyridamole and dexamethasone together.
Embodiment 3
[0065] Recipe: Ubenimex is 1mg, 10mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1600mg or 3200mg respectively, and dexamethasone is 0.1mg, 1mg, 10mg, 20mg, 40mg, 80mg or 160mg respectively. Stir Ubenimex and Dexamethasone to mix.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses an antitumor drug with double active components, and an application thereof. The antitumor drug comprises an independent first active component and an independent second active component. The independent first active component comprises at least two of A, B and C. The A comprises Dipyridamole and pharmaceutically acceptable derivatives of Dipyridamole or pharmaceutically acceptable analogues of Dipyridamole or pharmaceutically acceptable salts of Dipyridamole. The B comprises Ubenimex bestatin and pharmaceutically acceptable derivatives of Ubenimex bestatin or pharmaceutically acceptable analogues of Ubenimex bestatin or pharmaceutically acceptable salts of Ubenimex bestatin. The C comprises Dexamethasone and pharmaceutically acceptable derivatives of Dexamethasone or pharmaceutically acceptable analogues of Dexamethasone. The independent second active component comprises Taxol, ADM, DDP, MMC, 5-FM, Gemcitabine or a tyrosine kinase inhibitor. The antitumor drug provided by the invention can effect on multiple targets and multiple paths, and thus antineoplastic effects of the antitumor drug are clear and obvious.
Description
technical field [0001] The invention relates to a medicine with antitumor effect, in particular to an antitumor medicine comprising dipyridamole, ubenimex and dexamethasone and an antitumor chemotherapeutic medicine. Background technique [0002] The toxicity of currently clinically used antitumor drugs is a prominent problem in tumor chemotherapy. Finding its own low toxicity and acting on specific links or molecular targets in the tumor microenvironment to improve the anti-tumor effect or reduce its toxicity has become a new way to study anti-tumor drugs, and it is also an urgent need for clinical treatment of tumors. [0003] Malignant tumor is a common disease that seriously threatens human health. In today's world, there is an urgent need for anti-tumor drugs. According to the data in 2007, there were 12 million newly diagnosed cancer patients in the world, and 7.6 million people died of cancer. According to the data of the top ten disease mortality and cause of deat...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.